Amicus Therapeutics Inc (MEX:FOLD)
MXN 208.8 0 (0%) Market Cap: 60.68 Bil Enterprise Value: 64.66 Bil PE Ratio: 0 PB Ratio: 16.63 GF Score: 78/100

Amicus Therapeutics Inc at Barclays Global Healthcare Conference Transcript

Mar 12, 2019 / 12:00PM GMT
Jason Eron Zemansky
Barclays Bank PLC, Research Division - Research Analyst

Well, good morning, everyone. It's my distinct pleasure to start us off with the conference here with certainly one of the more uplifting stories, I think, in all of biotech, but joining me today from Amicus Therapeutics is Daphne Quimi and Jeff Castelli. Thank you so much for joining us.

Jeffrey P. Castelli
Amicus Therapeutics, Inc. - Chief Portfolio Officer & Head of Gene Therapy

Thank you.

Jason Eron Zemansky
Barclays Bank PLC, Research Division - Research Analyst

My name is Jason Zemansky. I am an associate on Geoff Meacham's team, large cap biopharma analyst at Barclays.

So I think we should just dive into the questions.

Questions & Answers

Jason Eron Zemansky
Barclays Bank PLC, Research Division - Research Analyst

So certainly, a large milestone in Amicus' story was the commercial approval of Galafold last August. Can you tell us a little bit about the feedback

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot